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BACKGROUND: Blood concentrations of cardiac troponin above the 99th 
percentile are a key criterion for the diagnosis of acute myocardial injury and 
infarction. Troponin concentrations, even below the 99th percentile, predict 
adverse outcomes in patients and the general population. Elevated troponin 
concentrations are commonly observed after endurance exercise, but the 
clinical significance of this increase is unknown. We examined the association 
between postexercise troponin I concentrations and clinical outcomes in long-
distance walkers.
METHODS: We measured cardiac troponin I concentrations in 725 participants 
(61 [54–69] yrs) before and immediately after 30 to 55 km of walking. We 
tested for an association between postexercise troponin I concentrations 
above the 99th percentile (>0.040 µg/L) and a composite end point of all-cause 
mortality and major adverse cardiovascular events (myocardial infarction, 
stroke, heart failure, revascularization, or sudden cardiac arrest). Continuous 
variables were reported as mean ± standard deviation when normally 
distributed or median [interquartile range] when not normally distributed.
RESULTS: Participants walked 8.3 [7.3–9.3] hours at 68±10% of their 
maximum heart rate. Baseline troponin I concentrations were >0.040 µg/L 
in 9 participants (1%). Troponin I concentrations increased after walking 
(P<.001), with 63 participants (9%) demonstrating a postexercise troponin 
concentration >0.040 µg/L. During 43 [23–77] months of follow-up, 62 
participants (9%) experienced an end point; 29 died and 33 had major 
adverse cardiovascular events. Compared with 7% with postexercise troponin 
I ≤0.040 µg/L (log-rank P<.001), 27% of participants with postexercise 
troponin I concentrations >0.040 µg/L experienced an end point. The 
hazard ratio was 2.48 (95% CI, 1.29–4.78) after adjusting for age, sex, 
cardiovascular risk factors (hypertension, hypercholesterolemia or diabetes 
mellitus), cardiovascular diseases (myocardial infarction, stroke, or heart 
failure), and baseline troponin I concentrations.
CONCLUSIONS: Exercise-induced troponin I elevations above the 99th 
percentile after 30 to 55 km of walking independently predicted higher 
mortality and cardiovascular events in a cohort of older long-distance 
walkers. Exercise-induced increases in troponin may not be a benign 
physiological response to exercise, but an early marker of future mortality and 
cardiovascular events.
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Cardiac troponin is a protein that facilitates cardio-myocyte contraction. Dynamic changes in circulat-ing troponin concentrations with at least 1 value 
exceeding the 99th percentile (the upper reference limit 
[URL]) in a clinical setting consistent with myocardial isch-
emia, are used to diagnose myocardial infarction, whereas 
a value above the URL alone indicates myocardial injury.1 
Even cardiac troponin values below the URL are associ-
ated with increased mortality and cardiovascular disease 
(CVD) morbidity in the general2 and patient population.3–5
Physical activity and exercise are associated with sig-
nificant reductions in cardiovascular events6,7 and with 
increased longevity.8,9 Paradoxically, multiple studies 
have shown that exercise acutely increases troponin 
concentrations,10 after a brief or long exercise duration, 
performed at either moderate or high-intensity.10,11 
Such exercise-induced increases in troponin concen-
trations are considered benign because they occur fre-
quently, are present in (apparently) healthy individuals, 
and are not accompanied by clinical symptoms. Nev-
ertheless, the mechanisms and clinical significance of 
exercise-induced increases in troponin are incompletely 
understood.11,12 We examined the association between 
postexercise troponin concentrations above the URL 
and clinical outcomes in a heterogeneous cohort of old-
er long-distance walkers. We also identified participant 
and exercise characteristics associated with postexer-
cise troponin concentrations above the URL.
METHODS
Study Population
The Nijmegen Four Days Marches is the largest walking 
event in the world (http://www.4daagse.nl/en/). Marchers 
in the 2008 to 2016 events were recruited by social media 
and website advertisement. Participants in the Nijmegen 
Marches walked 30, 40, 50, or 55 km per day, depending 
on age and sex, for 4 consecutive days. For this study, we 
only performed measurements on the first walking day. 
Participants self-selected their pace and rest times. Subjects 
completed a questionnaire about their cardiovascular health 
status and prescribed medications. This information was used 
to categorize individuals as participants with CVD (defined as 
a diagnosis of myocardial infarction, stroke, or heart failure), 
participants with cardiovascular risk factors ([CVRF] defined as 
treated hypertension, hypercholesterolemia, or diabetes mel-
litus), or participants without CVD and CVRF at baseline (con-
trols). Participants provided written informed consent. The 
medical ethical committee of the Radboud University Medical 
Center approved the study (NL18245.091.07). The study was 
conducted in accordance with the Declaration of Helsinki. The 
data that support the findings of this study are available from 
the corresponding author upon reasonable request.
Study Procedures
One or 2 days before the event (ie, baseline), body mass (Seca 
888 Scale; Seca, Hamburg, Germany) and height were mea-
sured. Body mass was also measured directly before and after 
walking to provide a surrogate of change in hydration sta-
tus.13 A venous blood sample (10 mL) was drawn from an 
antecubital vein at baseline and ~10 minutes after the finish 
of the first walking day (postexercise). Blood samples were 
collected in serum-gel Vacutainer tubes and allowed to clot 
for ~45 minutes. After centrifugation, serum was aliquoted, 
frozen (all directly done on-site), and stored at −80°C for later 
analysis (after serum from the last finisher was collected). 
Troponin concentrations were analyzed using a contem-
porary troponin I assay (ADVIA Centaur TnI-Ultra; Siemens 
Healthcare Diagnostics, The Hague, The Netherlands) with an 
established URL of 0.040 µg/L according to the manufacturer. 
The coefficient of variation is 8.8% at the URL and 10% at 
0.030 µg/L. The analytical limit of detection is 0.006 µg/L. 
The assay does report values <0.006 µg/L and these values 
were used to adjust for baseline troponin concentrations in 
the multivariable analyses.
Start and finish times were used to determine exer-
cise duration and calculate walking speed. Heart rate was 
recorded every 5 km along the route using a 2-channel 
electrocardiographic chest band (Polar Electro Oy; Kempele, 
Finland). Exercise intensity was calculated as average heart 
rate during exercise divided by estimated maximum heart rate 
(208−0.7 × age).14
Clinical Outcomes
The primary study end point was a composite of all-cause 
mortality and major adverse cardiovascular events (MACE). 
Survival status of study participants was retrieved from the 
Dutch population register. The final survival assessment was 
performed on December 13, 2018, ~6 months after the lat-
est annual questionnaire (July 2018) to ensure that those 
individuals who did not complete the questionnaires had not 
died. Information about MACEs were collected from annual 
questionnaires sent to study participants and were defined 
as myocardial infarction, stroke, heart failure, revasculariza-
tion (both acute and elective), or sudden cardiac arrest during 
Clinical Perspective
What Is New?
• Postexercise troponin I concentrations above the 
99th percentile were found in 9% of the partici-
pants, and 27% of those participants died or had 
major adverse cardiovascular events during follow-
up compared with 7% of participants with postex-
ercise troponin I below the 99th percentile.
• Greater exercise-induced changes in troponin I 
concentrations were associated with lower event-
free survival.
What Are the Clinical Implications?
• The present study suggests that exercise-induced 
increase in troponin may not be a benign physi-
ological response to exercise, but an early marker 
of future mortality and cardiovascular events.
• Higher concentrations of postexercise troponin 
may represent myocardial injury because of under-
lying, subclinical, cardiac pathology.
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follow-up. We evaluated medication use to ensure it matched 
the reported diagnoses. For the primary end point, partici-
pants were followed until first MACE or death, and those 
without an end point were censored on the date of the last 
completed questionnaire. Secondary end points were the 
individual components of the composite end point, all-cause 
mortality, with follow-up until date of death or final survival 
assessment (regardless of the date of the last completed 
questionnaire), and MACE, with follow-up until date of first 
event or last completed questionnaire.
Statistical Analysis
All variables were visually inspected for normality and checked 
for kurtosis and skewness. Continuous variables were reported 
as mean±SD when normally distributed or median [interquar-
tile range] when not normally distributed and categorical vari-
ables were presented as proportions. Depending on whether 
data were normally distributed, t tests or Mann–Whitney U 
tests were used to compare continuous variables. Pearson 
Chi-Square tests were used to compare categorical variables.
Kaplan–Meier curves were generated to evaluate and 
depict unadjusted survival plots of the composite end point of 
all-cause mortality and MACE for postexercise troponin con-
centrations >0.040 µg/L and ≤0.040 µg/L. Similar procedures 
were performed for the secondary end points, the individual 
components mortality and MACE. Cox proportional-hazards 
regression analyses were performed to calculate unadjusted 
and adjusted hazard ratios for primary and secondary end 
points. First, univariable Cox regression analysis of participant 
characteristics were used to identify potential confounders of 
the association between postexercise troponin I and clinical 
outcomes. Variables that were associated (P<0.10) with the 
primary end point were included in a multivariable analysis. 
We included postexercise troponin I and the potential con-
founders, and subsequently removed variables with a P>0.10 
association following a stepwise approach. Remaining vari-
ables were included in the multivariable-adjusted model. 
Sensitivity analyses were performed to evaluate the robust-
ness of our findings. To ensure that the results were not 
attributable to including individuals with CVD, stratified anal-
yses were performed in individuals without CVD at baseline. 
Additionally, explorative analyses were performed to inves-
tigate whether detectable troponin I concentrations below 
the URL were associated with the primary and secondary end 
points by performing the analyses for 3 groups of postexer-
cise troponin I concentrations: <0.006, 0.006 to 0.040, and 
>0.040 µg/L. Moreover, Kaplan–Meier curves and Cox pro-
portional-hazards models were generated to investigate the 
association between delta (postexercise minus baseline) tro-
ponin I concentrations (>0.010, >0.020, >0.030, and >0.040 
µg/L) and the primary and secondary end points.
Binary logistic regression was used to calculate unadjusted 
and multivariable adjusted odds ratios for the association 
between participant and exercise characteristics and postex-
ercise troponin I values above the URL. First, univariable logis-
tic regression analysis of variables was used to select potential 
predictors for multivariable analysis. Variables that were asso-
ciated (P<0.10) with postexercise troponin I values above the 
URL were subsequently included in a multivariable backward 
logistic regression analysis to gain insight into which variables 
could independently predict postexercise troponin I concen-
trations >0.040 µg/L.
All statistical analyses were performed using SPSS Statistics 
24 (SPSS, Inc., Chicago, Illinois). Statistical significance was 
assumed at P<0.05.
RESULTS
A total of 804 participants were recruited (Figure 1). 
Seventy-nine individuals who were alive at the end of 
follow-up declined to complete the additional annual 
questionnaires on cardiovascular events. Therefore, 
725 participants were included in the analyses of the 
primary composite end point of all-cause mortality and 
MACE (Table 1). Participants were 61 [54–69] years old 
at baseline and 62% were male (Table 1). A total of 
14% had CVD, 26% had only CVRF, and 60% had 
no CVD or CVRF at baseline (controls). For the primary 
composite end point, participants had a median fol-
low-up of 43 [23–77] months. The total cohort of 804 
participants was included in the analyses of only all-
cause mortality as a secondary end point (52 [28–100] 
months follow-up). Eleven participants died before 
completion of the first questionnaire for assessment 
of MACE, thus 714 participants were included in the 
analyses of the secondary end point of only MACE (43 
[23–77] months follow-up).
Exercise Characteristics and Troponin
Participants walked 8.3 [7.3–9.3] hours at 68±10% of 
their predicted maximum heart rate. Baseline troponin 
I concentrations were detectable (≥0.006 µg/L) in 233 
(33%) participants, with 9 participants (1%) demon-
strating a value >0.040 µg/L. At baseline, participants 
with CVD had detectable troponin concentrations more 
frequently than those with CVRF, who had detectable 
troponin concentrations more frequently than controls. 
Frequency of troponin concentrations >0.040 µg/L did 
not differ between groups at baseline (Figure 2). Tro-
ponin concentrations increased after exercise (P<0.001) 
and 418 participants (58%) had detectable troponin 
concentrations, with 63 participants (9%) demonstrat-
ing a value >0.040 µg/L. Postexercise, troponin con-
centrations increased in all groups (P<0.001) and were 
more frequently detectable in participants with CVD 
and CVRF, and more often >0.040 µg/L in those with 
CVD compared with controls (Figure 2).
Clinical Outcomes
During follow-up, 62 participants reached the primary 
end point: 29 died and 33 had MACE. First MACE dur-
ing follow-up included 6 myocardial infarctions (18%), 
17 strokes (52%), 4 heart failure diagnoses (12%), 5 
revascularizations (15%), and 1 resuscitated sudden 
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cardiac arrest (3%). Twenty-one participants with CVD 
(20%) died or had MACE, compared with 24 (13%) 
with CVRF and 17 (4%) controls (P<0.001). A total of 
27% of the participants with postexercise troponin 
>0.040 µg/L died or had MACE, compared with 7% 
of those with a concentration ≤0.040 µg/L. Unadjusted 
Kaplan–Meier analyses revealed a significantly lower 
event-free survival among participants who had postex-
ercise troponin I >0.040 µg/L compared with those 
≤0.040 µg/L (P<0.001; Figure  3). Similar results were 
observed for the secondary end points of all-cause mor-
tality (Figure I in the online-only Data Supplement) and 
MACE (Figure II in the online-only Data Supplement).
Cox proportional-hazards models showed associa-
tions between the primary end point and the following 
variables: baseline troponin, postexercise troponin, age, 
sex, body mass index, presence of CVRF and CVD, and 
smoking (Table I in the online-only Data Supplement). 
After multivariable adjustment, baseline and postexercise 
troponin, age, sex, and presence of CVD and CVRF re-
mained independently associated with the primary end 
point (Table I in the online-only Data Supplement). Simi-
lar Cox proportional-hazards models were made for the 
secondary end points mortality (Table II in the online-only 
Data Supplement) and MACE (Table III in the online-only 
Data Supplement). The crude hazard ratio of postexercise 
troponin I >0.040 µg/L with all-cause mortality and MACE 
was 5.21 (95% CI, 2.96–9.17). After adjustment for age, 
sex, and presence of CVD and CVRF, the hazard ratio was 
3.21 (95% CI, 1.79–5.77), which further decreased to 
2.48 (95% CI, 1.29–4.78) after additional adjustment for 
baseline troponin (Table 2). Associations between postex-
ercise troponin >0.040 µg/L and the individual compo-
nents of the primary end point were stronger for MACE 
compared with all-cause mortality (Table 2).
Sensitivity analyses, excluding individuals with CVD 
at baseline, further reinforced our findings. Of the par-
ticipants without CVD at baseline, 26% of those with 
postexercise troponin I >0.040 µg/L died or had MACE, 
compared with 5% of those with troponin ≤0.040 
µg/L. Unadjusted Kaplan–Meier analyses revealed a sig-
nificantly lower event-free survival among participants 
who had postexercise troponin >0.040 µg/L compared 
with those ≤0.040 µg/L (p<.001, Figure III in the online-
only Data Supplement). The adjusted hazard ratio for 
postexercise troponin I >0.040 µg/L was 3.28 (95% 
CI, 1.48–7.29) for all-cause mortality and MACE, 0.51 
(95% CI, 0.10–2.52) for all-cause mortality, and 7.42 
(95% CI, 2.57–21.37) for MACE (Table IV in the online-
only Data Supplement).
Exploratory analyses of postexercise troponin I con-
centrations <0.006, 0.006 to 0.040, and >0.040 µg/L 
suggested that the risk for individuals with postexercise 
troponin I concentrations 0.006 to 0.040 µg/L did not 
differ from those with postexercise troponin I <0.006 
µg/L (Figure IV and Table V in the online-only Data 
Supplement). Kaplan–Meier curves and Cox regres-
sion analyses of delta troponin concentrations demon-
strated a lower event-free survival for participants with 
higher delta troponin concentrations and hazard ratios 
Figure 1. Flowchart of study procedures.
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increased when using higher cut-off values for Δ tropo-
nin concentrations (Figure 4, Table 3).
Factors Associated With Postexercise 
Troponin
Of the total cohort of 804 participants, 72 participants 
had postexercise troponin I values >0.040 µg/L and 
those individuals were older, more often male, heavier, 
more often had CVD and CVRF, had higher baseline 
troponin values, walked at a higher exercise intensity, 
and lost more body mass during walking (Table VI in 
the online-only Data Supplement). These findings were 
confirmed by logistic regression analysis (Table VII in the 
online-only Data Supplement) as age (odds ratio, 1.07; 
95% CI, 1.04–1.10), body mass (odds ratio, 1.04; 95% 
Table 1. Participant and Exercise Characteristics, Total and Split, for Cardiac Troponin I Below and Above the Upper 
Reference Limit
Participant and Exercise 
Characteristics Total
Postexercise Troponin I 
≤0.040 µg/L
Postexercise Troponin I 
>0.040 µg/L P Value
N 725 662 63  
Age, y 61.4 [54.4–69.1] 61.1 [54.1–68.3] 66.4 [60.0–81.3] <0.001
Sex, n (%) <0.001
  Male 446 (62) 393 (59) 53 (84)  
  Female 279 (38) 269 (41) 10 (16)  
Height, m 1.73 (0.09) 1.73 (0.09) 1.75 (0.07) 0.10
Body mass, kg 79.1 (14.5) 78.6 (14.5) 83.8 (14.0) 0.01
Body mass index, kg/m2 26.2 (3.6) 26.1 (3.6) 27.2 (3.7) 0.01
Smoking, n (%) 0.79
  Never 289 (41) 266 (42) 23 (37)  
  Current smoking 30 (4) 27 (4) 3 (5)  
  Previously smoked 383 (55) 347 (54) 36 (58)  
Cardiovascular risk factors, n (%) 258 (36)* 224 (34) 34 (54) 0.002
  Hypertension 173 (24) 145 (22) 28 (44) <0.001
  Hypercholesterolemia 106 (15) 90 (14) 16 (25) 0.02
  Diabetes mellitus 64 (9) 56 (8) 8 (13) 0.37
Cardiovascular diseases, n (%) 104 (14) 87 (13) 17 (27) 0.005
  Myocardial infarction 65 (9) 54 (8) 11 (18) 0.03
  Stroke 26 (4) 22 (3) 4 (6) 0.38
  Heart failure 33 (5) 27 (4) 6 (10) 0.10
Baseline troponin I, n (%)    <0.001
≥0.006–0.040 µg/L 224 (31) 191 (30) 33 (53)  
>0.040 µg/L 9 (1) 3 (1) 6 (10)  
Walking distance, n (%) 0.18
  30 km 324 (45) 289 (44) 35 (56)  
  40 km 300 (41) 278 (42) 22 (35)  
  50 or 55 km 101 (14) 95 (14) 6 (10)  
Walking duration, h 8.3 [7.3–9.3] 8.3 [7.4–9.3] 8.3 [6.9–9.0] 0.25
Walking speed, km/h 4.4 [4.0–4.9] 4.4 [4.0–4.9] 4.3 [3.7–5.0] 0.52
Exercise intensity, % 67.8 (10.3) 67.5 (9.9) 71.2 (13.0) 0.01
Change in body mass, % −1.0 (1.0) −1.0 (1.0) −1.3 (0.9) 0.02
Postexercise troponin I, n (%) <0.001
  ≥0.006–0.040 µg/L 355 (49) 355 (54) 0 (0)  
  >0.040 µg/L 63 (9) 0 (0) 63 (100)  
Body mass index = body mass/length2. Exercise intensity = average heart rate/maximum estimated heart rate. Continuous variables 
were reported as mean (SD) when normally distributed or median (interquartile range) when not normally distributed.
*Note that this group contains individuals with only cardiovascular risk factors (26%) and cardiovascular disease with cardiovascular 
risk factors (10%).
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CI, 1.02–1.07), baseline troponin (odds ratio, 1.08; 
95% CI, 1.05–1.11), exercise intensity (odds ratio, 
1.05; 95% CI, 1.02–1.08), and change in body mass 
during exercise (odds ratio, 0.69; 95% CI, 0.50–0.94) 
were independently associated with postexercise tropo-
nin I >0.040 µg/L (full model R2=0.32; Table VII in the 
online-only Data Supplement).
DISCUSSION
Elevated troponin concentrations are frequently observed 
after exercise of varying duration and intensity. This exer-
cise-associated elevation has commonly been considered 
to represent a benign phenomenon11,12. We examined the 
potential clinical relevance of exercise-induced troponin 
elevations and found that postexercise troponin I concen-
trations above the URL after recreational walking exercise 
were associated with a lower event-free survival. This as-
sociation was independent of age, sex, presence of CVD 
and CVRF, and baseline troponin concentrations. The oc-
currence of postexercise troponin I >0.040 µg/L was di-
rectly associated with age, body mass, exercise intensity, 
loss of body mass during exercise, and baseline troponin 
concentrations. These findings indicate that postexercise 
troponin I concentrations above the URL may be a marker 
of future mortality and cardiovascular events.
Troponin and Clinical Outcomes
With the exception of exercise-induced troponin increase, 
troponin elevation is associated with increased risks for 
mortality and cardiovascular morbidity.2–5 We found that 
a greater exercise-induced troponin I release and postex-
ercise troponin I concentrations above the URL are also 
associated with a higher incidence of mortality and cardio-
vascular events during follow-up. Importantly, this associa-
tion remained significant even after adjusting for baseline 
values. This observation suggests that exercise-induced 
troponin concentrations provide prognostic information 
beyond that of baseline troponin. Higher concentrations 
Figure 2. Prevalence of baseline and postexercise cardiac troponin I 
values above the limit of detection (≥0.006 µg/L) and upper reference 
limit (>0.040 µg/L) across cardiovascular health groups.  
At baseline, participants with cardiovascular diseases (CVD) more frequently 
had detectable (≥0.006 µg/L) troponin I concentrations compared with 
those with risk factors (CVRF), who more frequently had detectable troponin 
concentrations than participants without CVD and CVRF at baseline (controls). 
Postexercise troponin I concentrations were more frequently detectable in 
participants with CVD and CVRF compared with controls (A). At baseline, 
troponin I concentrations >0.040 µg/L were rare and did not differ across 
groups. Participants with CVD more often had postexercise values >0.040 
µg/L compared with controls (B). *P<0.05 compared with controls; †P<0.05 
compared with CVRF.
Figure 3. Unadjusted Kaplan–Meier estimates of 
all-cause mortality and major adverse cardiovas-
cular events during follow-up.  
Participants with exercise-induced cardiac troponin I 
concentrations above the upper reference limit (>0.040 
µg/L) had a significantly lower event-free survival 
compared with those below the upper reference limit 
(≤0.040 µg/L).
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of postexercise troponin may represent myocardial inju-
ry because of underlying, subclinical, cardiac pathology. 
This hypothesis is supported by our finding of a higher 
incidence of postexercise troponin >0.040 µg/L in par-
ticipants with CVD, but also the stronger association 
between postexercise troponin >0.040 µg/L and MACE 
versus mortality. Exposure of individuals to bouts of exer-
cise can unmask myocardial vulnerability,15 which would 
remain unnoticed under resting conditions. Patients with 
coronary artery disease and exercise-induced myocardial 
ischemia may have higher postexercise troponin I concen-
trations than those without ischemia.16 Moreover, a recent 
pilot study reported that high postexercise troponin I 
concentrations were associated with occult coronary ar-
tery disease in recreational cyclists.17 Möhlenkamp et 
al found higher postexercise troponin I concentrations in 
marathon runners with myocardial late gadolinium en-
hancement.18 These findings suggest that postexercise 
troponin I concentrations above the URL could indicate 
the presence of underlying (subclinical) cardiac disease.
Alternatively, exercise-induced troponin elevations 
could also represent acute myocardial injury, indepen-
dent of myocardial vulnerability. This interpretation fits 
with the ongoing question as to whether high-volume 
high-intensity exercise training may cause detrimental 
cardiac adaptions.10,19 A higher prevalence of coronary 
atherosclerosis,20 myocardial fibrosis,21 and atrial fibrilla-
tion22 have been reported in amateur athletes reporting 
a large lifelong exercise volume. Long-term, high-vol-
ume exercise could produce repetitive myocardial injury 
leading to these cardiac maladaptations. Additional 
studies are necessary to test this hypothesis.
Potential Mechanisms of Troponin 
Release
We found that age, body mass, baseline troponin, ex-
ercise intensity, and change in body mass during ex-
ercise were independently associated with a postex-
ercise troponin I >0.040 µg/L. There are 5 proposed 
mechanisms of exercise-induced troponin release into 
the bloodstream: (1) myocyte necrosis, (2) apoptosis, 
(3) cellular release of troponin degradation products, 
(4) increased cellular membrane permeability, and (5) 
release of membranous blebs.11,23,24 Myocyte necrosis 
and apoptosis represent irreversible myocardial injury, 
whereas the other mechanisms are characterized by 
reversible cardiomyocyte damage.12 Postexercise tro-
ponin T concentrations in marathon runners are com-
posed of small, degraded, T molecules.25 This obser-
vation supports the hypothesis that exercise induces 
reversible myocardial injury, allowing degraded tropo-
nin molecules to exit the cardiomyocyte. For example, 
increases in preload can cause troponin degradation26 
and small troponin fragments could pass through a 
cellular membrane with normal membrane integrity.23 
Alternatively, exercise could increase membrane perme-
ability by stimulating stretch-responsive integrins27 or by 
causing cell “wounds” (ie, transient disruptions of the 
membrane),28 allowing intact27 or degraded26 troponin 
fragments to enter the bloodstream. The frequency at 
which these wounds occur increases with higher heart 
rate and contractility, and may contribute to myocyte 
hypertrophy.28 Our finding that a higher exercise inten-
sity was independently associated with an increased 
prevalence of troponin I above the URL supports the 
hypothesis that exercise may induce transient troponin 
elevations attributable to transient increases in cardio-
myocyte membrane permeability.
Clinical Relevance
We demonstrated that the prevalence of troponin I 
concentrations >0.040 µg/L increased from 1% at 
baseline to 9% postexercise, and that postexercise 
troponin I concentrations >0.040 µg/L were associ-
ated with future mortality and MACE. Our sensitiv-
ity analyses further confirmed the outcomes of our 
Table 2. Unadjusted and Multivariable-Adjusted Associations Between Postexercise Troponin I Concentrations Above the Upper 
Reference Limit (>0.040 µg/L) and Incidence of All-Cause Mortality and Major Adverse Cardiovascular Events, and Mortality and Major 
Adverse Cardiovascular Events Individually
Unadjusted Model 1* Model 2†
Hazard Ratio  
(95% CI) P  Value
Hazard Ratio  
(95% CI) P Value
Hazard Ratio  
(95% CI) P Value
  Mortality and MACE N=725 N=725 N=701
Postexercise troponin I >0.040 µg/L 5.21 (2.96–9.17) <0.001 3.21 (1.79–5.77) <0.001 2.48 (1.29–4.78) 0.01
  Mortality N=804 N=793 N=764
Postexercise troponin I >0.040 µg/L 2.92 (1.19–7.19) 0.02 1.44 (0.56–3.70) 0.44 1.09 (0.38–3.10) 0.88
  MACE N=714 N=714 N=690
Postexercise troponin I >0.040 µg/L 7.09 (3.89–14.86) <0.001 4.82 (2.24–10.37) <0.001 3.75 (1.56–9.02) 0.003
MACE were myocardial infarction, stroke, heart failure, aborted cardiac arrest, or revascularization. CI indicates confidence interval; and MACE, major 
adverse cardiovascular events. 
*Adjusted for age, sex, baseline cardiovascular diseases, and cardiovascular risk factors.
†Adjusted for model 1 and for baseline troponin I concentrations (continuous variable). Some study participants had missing data of confounding 
factors, so n=11 (model 1) and n=29 (model 2) were excluded from the adjusted Mortality analyses, whereas n=24 (model 2) were excluded from the 
Mortality and MACE and MACE analyses.
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study, as we found that the association between 
postexercise troponin >0.040 µg/L and mortality and 
MACE was even stronger in participants without CVD 
at baseline. These findings suggest that exercise-
induced troponin I is an independent marker of fu-
ture mortality and MACE among individuals with and 
without CVD.
The incidence of exercise-induced troponin I con-
centrations above the URL was relatively low (9%) in 
our study of long-distance walkers. Studies in mara-
thon runners have reported that >50% of runners have 
postexercise troponin concentrations above the URL29–31 
and it is not clear whether such a high prevalence of 
exercise-induced troponin increases has similar clinical 
predictive value. Möhlenkamp et al evaluated 6-year 
coronary event rates between marathon runners with 
postexercise cardiac troponin I above and below the 
median and found no differences in their cohort, but 
they followed only 74 marathon runners of whom 6 
had an event.18 Consequently, additional studies are 
needed to confirm our observation in different popula-
tions with different exercise exposures.
It is currently unclear how these findings impact tro-
ponin testing before and after clinical stress testing. A 
recent meta-analysis found no difference in poststress 
(either bicycle exercise or pharmacological test) troponin 
concentrations in individuals with inducible or noninduc-
ible myocardial ischemia.32 However, only a nonsignifi-
cant 0 to 2 ng/L change in troponin concentrations was 
found, suggesting that the exercise intensity may not 
have been sufficiently high to maximally stress the heart 
and identify individuals at risk. Furthermore, postex-
ercise troponin concentrations were not evaluated as 
above versus below the URL. Also, troponin release may 
not be solely attributable to myocardial ischemia. Thus, 
additional studies are needed to evaluate our observa-
tion in the setting of clinical stress/exercise testing and 
whether measurement of cardiac troponin concentra-
tions provides additional prognostic information.
Limitations
The main limitation of our study is that troponin I was 
measured using a contemporary assay. High-sensitive 
Figure 4. Unadjusted Kaplan–Meier estimates of all-cause mortality and major adverse cardiovascular events during follow-up.  
Participants with Δ (postexercise minus baseline) cardiac troponin I concentrations >0.010 µg/L (A), >0.020 µg/L (B), >0.030 µg/L (C), and >0.040 µg/L (D).
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assays are capable of measuring troponin concentra-
tions in more than 50% of healthy individuals, but it 
is important to emphasize that the coefficient of varia-
tion at the URL is comparable for our contemporary 
assay and other the high-sensitive assays (8.8% versus 
5–10%).33 Nevertheless, we cannot predict how the 
use of a high-sensitive assays would affect our results.
Our study is also limited by sample size, a relatively 
short duration of follow-up and a low event rate. Nev-
ertheless, this is the largest study to investigate clini-
cal outcomes of exercise-induced troponin elevations. 
Another limitation is that we used questionnaires to 
record cardiovascular morbidity. However, we evalu-
ated medication use to cross-validate the self-reported 
diagnoses. Findings from this study cannot be directly 
extrapolated to other populations and/or other types 
of exercise. Higher-volume, higher-intensity exercise 
produces a higher prevalence of postexercise troponin 
concentrations above the URL. Individuals able to en-
gage in such intense exercise and their CVD outcomes 
are likely to be different from the older long-distance 
walkers that we studied. Training experience can affect 
the exercise-induced troponin response34,35 and is po-
tentially associated with clinical outcomes, but we did 
not have detailed training records for our participants. 
However, training experience may also be a surrogate 
for exercise intensity and/or duration and although we 
found that exercise intensity was significantly associ-
ated with troponin I concentrations above the URL, it 
was not significantly associated with clinical outcomes 
in the univariate Cox regression analysis.
Conclusions
Older long-distance walkers with exercise-induced tro-
ponin I elevations above the URL after 30 to 55 km of 
walking exercise had a lower event-free survival and 
this association was independent of age, sex, presence 
of CVD and CVRF, and baseline troponin concentra-
tions. These findings suggest that postexercise troponin 
concentrations above the URL may be an independent 
marker of future mortality and cardiovascular events, 
even in individuals without established CVD.
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Table 3. Unadjusted and Multivariable-Adjusted Associations between Δ Troponin I Concentrations and Incidence of All-Cause Mortality and 
Major Adverse Cardiovascular Events, and Mortality and Cardiovascular Events Individually
Unadjusted Model 1* Model 2†
Hazard Ratio  
(95% CI) P Value
Hazard Ratio  
(95% CI) P Value
Hazard Ratio  
(95% CI) P Value
Mortality and MACE N=701 N=701 N=701
  Delta troponin I >0.010 µg/L 2.15 (1.29–3.58) 0.003 1.47 (0.87–2.48) 0.15 1.52 (0.90–2.55) 0.12
  Delta troponin I >0.020 µg/L 3.31 (1.93–5.69) <0.001 1.98 (1.13–3.46) 0.02 1.92 (1.10–3.43) 0.02
  Delta troponin I >0.030 µg/L 3.18 (1.72–5.91) <0.001 2.02 (1.08–3.80) 0.03 1.74 (0.92–3.27) 0.09
  Delta troponin I >0.040 µg/L 3.71 (1.82–7.58) <0.001 2.33 (1.12–4.83) 0.02 2.10 (1.01–4.35) 0.047
Mortality N=773 N=764 N=764
  Delta troponin I >0.010 µg/L 2.86 (1.37–5.95) 0.005 1.80 (0.84–3.86) 0.13 1.78 (0.83–3.80) 0.14
  Delta troponin I >0.020 µg/L 2.57 (1.17–5.64) 0.02 1.31 (0.57–3.02) 0.52 1.25 (0.54–2.87) 0.61
  Delta troponin I >0.030 µg/L 1.55 (0.54–4.45) 0.42 0.81 (0.27–2.40) 0.70 0.71 (0.24–2.12) 0.54
  Delta troponin I >0.040 µg/L 1.95 (0.59–6.43) 0.28 0.94 (0.28–3.22) 0.93 0.83 (0.24–2.87) 0.77
MACE N=690 N=690 N=690
  Delta troponin I >0.010 µg/L 1.61 (0.78–3.31) 0.20 1.16 (0.55–2.42) 0.70 1.14 (0.54–2.38) 0.73
  Delta troponin I >0.020 µg/L 3.72 (1.78–7.81) 0.001 2.55 (1.19–5.46) 0.02 2.24 (1.04–4.82) 0.04
  Delta troponin I >0.030 µg/L 4.78 (2.19–10.45) <0.001 3.15 (1.42–6.96) 0.005 2.48 (1.09–5.64) 0.03
  Delta troponin I >0.040 µg/L 5.18 (2.11–12.75) <0.001 3.76 (1.50–9.45) 0.005 2.78 (1.07–7.26) 0.04
MACE were myocardial infarction, stroke, heart failure, aborted cardiac arrest, or revascularization. Δ indicates postexercise minus baseline troponin concentration; 
CI, confidence interval; and MACE, major adverse cardiovascular events. 
*Adjusted for age, sex, baseline cardiovascular diseases and cardiovascular risk factors. 
†Adjusted for model 1 and for baseline troponin I concentrations (continuous variable). Some study participants had missing data of baseline troponin 
concentrations and confounding factors, so n=24 were excluded from Mortality and MACE and MACE analyses, whereas n=31 (unadjusted) and n=9 (model 1) were 
excluded from Mortality analyses.
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